Ouvrir dans le comparateur
Ce comparateur présente l'état de la littérature scientifique. Ce n'est pas un avis médical : seul un médecin peut dire ce qui convient à votre situation.

Minoxidil topique 5 % face à Minoxidil topique 1 %

2 essais les comparent directement, sur les mêmes patients. Voir Minoxidil topique 5 % · Voir Minoxidil topique 1 %

En bref

Chez 300 hommes japonais atteints d'alopécie androgénétique, un essai randomisé à risque de biais modéré (Tsuboi 2009) montre que le minoxidil topique 5 % fait significativement mieux que le 1 % : à 16 semaines, +22,3 cheveux gagnés par cm² contre +17,2 et +26,4 cheveux épais par cm² contre +21,2. Les effets indésirables attribués au traitement sont un peu plus fréquents sous 5 % (8,7 % contre 5,3 % à 24 semaines), sans différence significative, dont un eczéma de contact chez 3,3 % contre 2 % des hommes.

Votre profil

Tsuboi 2009

Essai randomisé, risque de biais modéré. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.

CritèreMinoxidil topique 5 %Minoxidil topique 1 %Écart
Gain de cheveux non-duvet depuis le départ16 semaines+26,4 cheveux par cm²
Voir la citation
Table3. Meanchangefrombaselineinhaircountatweek16(fullanalysisset) One-samplet-test† Efficacyvariableinhaircount 5%(n=142) Non-vellushaircount 26.4±1.7(23.1–29.8) P<0.001 Vellushaircount )4.7±1.3()7.3to)2.1) P<0.001 Terminalhaircount 16.1±1.4(13.3–18.8) P<0.001 Non-terminalhaircount 4.9±1.7(1.6–8.2) P=0.004 Totalhaircount 22.3±1.4(19.5–25.1) P<0.001 1%(n=144) Two-samplet-test‡ 21.2±1.5(18.3–24.1) 5.2(0.8–9.6) P<0.001 P=0.020 )4.0±1.2()6.5to)1.6) )0.7()4.2to2.9) P=0.001 P=0.712 12.2±1.0(10.2–14.2) 3.9(0.5–7.3) P<0.001 P=0.026 3.0±1.3(0.4–5.7) 1.9()2.4to6.1) P=0.025 P=0.384 17.2±1.3(14.6–19.8) 5.1(1.3–8.8) P<0.001 P=0.009 †Mean±standarderror(one-side95%confidenceinterval).‡Differenceinchangebetweengroups(two-side95%confidenceinterval).

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

+21,2 cheveux par cm²
Voir la citation
Table3. Meanchangefrombaselineinhaircountatweek16(fullanalysisset) One-samplet-test† Efficacyvariableinhaircount 5%(n=142) Non-vellushaircount 26.4±1.7(23.1–29.8) P<0.001 Vellushaircount )4.7±1.3()7.3to)2.1) P<0.001 Terminalhaircount 16.1±1.4(13.3–18.8) P<0.001 Non-terminalhaircount 4.9±1.7(1.6–8.2) P=0.004 Totalhaircount 22.3±1.4(19.5–25.1) P<0.001 1%(n=144) Two-samplet-test‡ 21.2±1.5(18.3–24.1) 5.2(0.8–9.6) P<0.001 P=0.020 )4.0±1.2()6.5to)1.6) )0.7()4.2to2.9) P=0.001 P=0.712 12.2±1.0(10.2–14.2) 3.9(0.5–7.3) P<0.001 P=0.026 3.0±1.3(0.4–5.7) 1.9()2.4to6.1) P=0.025 P=0.384 17.2±1.3(14.6–19.8) 5.1(1.3–8.8) P<0.001 P=0.009 †Mean±standarderror(one-side95%confidenceinterval).‡Differenceinchangebetweengroups(two-side95%confidenceinterval).

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Probablement réel
Gain de cheveux terminaux par cm²16 semaines+16,1 cheveux par cm²
Voir la citation
Table3. Meanchangefrombaselineinhaircountatweek16(fullanalysisset) One-samplet-test† Efficacyvariableinhaircount 5%(n=142) Non-vellushaircount 26.4±1.7(23.1–29.8) P<0.001 Vellushaircount )4.7±1.3()7.3to)2.1) P<0.001 Terminalhaircount 16.1±1.4(13.3–18.8) P<0.001 Non-terminalhaircount 4.9±1.7(1.6–8.2) P=0.004 Totalhaircount 22.3±1.4(19.5–25.1) P<0.001 1%(n=144) Two-samplet-test‡ 21.2±1.5(18.3–24.1) 5.2(0.8–9.6) P<0.001 P=0.020 )4.0±1.2()6.5to)1.6) )0.7()4.2to2.9) P=0.001 P=0.712 12.2±1.0(10.2–14.2) 3.9(0.5–7.3) P<0.001 P=0.026 3.0±1.3(0.4–5.7) 1.9()2.4to6.1) P=0.025 P=0.384 17.2±1.3(14.6–19.8) 5.1(1.3–8.8) P<0.001 P=0.009 †Mean±standarderror(one-side95%confidenceinterval).‡Differenceinchangebetweengroups(two-side95%confidenceinterval).

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

+12,2 cheveux par cm²
Voir la citation
Table3. Meanchangefrombaselineinhaircountatweek16(fullanalysisset) One-samplet-test† Efficacyvariableinhaircount 5%(n=142) Non-vellushaircount 26.4±1.7(23.1–29.8) P<0.001 Vellushaircount )4.7±1.3()7.3to)2.1) P<0.001 Terminalhaircount 16.1±1.4(13.3–18.8) P<0.001 Non-terminalhaircount 4.9±1.7(1.6–8.2) P=0.004 Totalhaircount 22.3±1.4(19.5–25.1) P<0.001 1%(n=144) Two-samplet-test‡ 21.2±1.5(18.3–24.1) 5.2(0.8–9.6) P<0.001 P=0.020 )4.0±1.2()6.5to)1.6) )0.7()4.2to2.9) P=0.001 P=0.712 12.2±1.0(10.2–14.2) 3.9(0.5–7.3) P<0.001 P=0.026 3.0±1.3(0.4–5.7) 1.9()2.4to6.1) P=0.025 P=0.384 17.2±1.3(14.6–19.8) 5.1(1.3–8.8) P<0.001 P=0.009 †Mean±standarderror(one-side95%confidenceinterval).‡Differenceinchangebetweengroups(two-side95%confidenceinterval).

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Probablement réel
Gain de densité depuis le départ16 semaines+22,3 cheveux par cm²
Voir la citation
Table3. Meanchangefrombaselineinhaircountatweek16(fullanalysisset) One-samplet-test† Efficacyvariableinhaircount 5%(n=142) Non-vellushaircount 26.4±1.7(23.1–29.8) P<0.001 Vellushaircount )4.7±1.3()7.3to)2.1) P<0.001 Terminalhaircount 16.1±1.4(13.3–18.8) P<0.001 Non-terminalhaircount 4.9±1.7(1.6–8.2) P=0.004 Totalhaircount 22.3±1.4(19.5–25.1) P<0.001 1%(n=144) Two-samplet-test‡ 21.2±1.5(18.3–24.1) 5.2(0.8–9.6) P<0.001 P=0.020 )4.0±1.2()6.5to)1.6) )0.7()4.2to2.9) P=0.001 P=0.712 12.2±1.0(10.2–14.2) 3.9(0.5–7.3) P<0.001 P=0.026 3.0±1.3(0.4–5.7) 1.9()2.4to6.1) P=0.025 P=0.384 17.2±1.3(14.6–19.8) 5.1(1.3–8.8) P<0.001 P=0.009 †Mean±standarderror(one-side95%confidenceinterval).‡Differenceinchangebetweengroups(two-side95%confidenceinterval).

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

+17,2 cheveux par cm²
Voir la citation
Table3. Meanchangefrombaselineinhaircountatweek16(fullanalysisset) One-samplet-test† Efficacyvariableinhaircount 5%(n=142) Non-vellushaircount 26.4±1.7(23.1–29.8) P<0.001 Vellushaircount )4.7±1.3()7.3to)2.1) P<0.001 Terminalhaircount 16.1±1.4(13.3–18.8) P<0.001 Non-terminalhaircount 4.9±1.7(1.6–8.2) P=0.004 Totalhaircount 22.3±1.4(19.5–25.1) P<0.001 1%(n=144) Two-samplet-test‡ 21.2±1.5(18.3–24.1) 5.2(0.8–9.6) P<0.001 P=0.020 )4.0±1.2()6.5to)1.6) )0.7()4.2to2.9) P=0.001 P=0.712 12.2±1.0(10.2–14.2) 3.9(0.5–7.3) P<0.001 P=0.026 3.0±1.3(0.4–5.7) 1.9()2.4to6.1) P=0.025 P=0.384 17.2±1.3(14.6–19.8) 5.1(1.3–8.8) P<0.001 P=0.009 †Mean±standarderror(one-side95%confidenceinterval).‡Differenceinchangebetweengroups(two-side95%confidenceinterval).

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Probablement réel
Dermatite de contact24 semaines3,3 % (5 sur 150)
Voir la citation
Table4. Adverseeventsrelatedtoinvestigationaldrug Group 5%(n=150) 1%(n=150) Incidenceofadverseevents 13(8.7) 8(5.3) Dermatological Subtotal 12(8.0) 4(2.7) Contactdermatitis 5(3.3) 3(2.0) Eczema 5(3.3) 1(0.7)

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

2 % (3 sur 150)
Voir la citation
Table4. Adverseeventsrelatedtoinvestigationaldrug Group 5%(n=150) 1%(n=150) Incidenceofadverseevents 13(8.7) 8(5.3) Dermatological Subtotal 12(8.0) 4(2.7) Contactdermatitis 5(3.3) 3(2.0) Eczema 5(3.3) 1(0.7)

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Non testé
Incidence d'un effet indésirable lié au traitement24 semaines8,7 % (13 sur 150)
Voir la citation
Table4. Adverseeventsrelatedtoinvestigationaldrug Group 5%(n=150) 1%(n=150) Incidenceofadverseevents 13(8.7) 8(5.3) Dermatological Subtotal 12(8.0) 4(2.7) Contactdermatitis 5(3.3) 3(2.0) Eczema 5(3.3) 1(0.7)

Citation complémentaire (significativite)

no significant difference between groups (v2-test: P = 0.258). The incidence of dermatological adverse

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

5,3 % (8 sur 150)
Voir la citation
Table4. Adverseeventsrelatedtoinvestigationaldrug Group 5%(n=150) 1%(n=150) Incidenceofadverseevents 13(8.7) 8(5.3) Dermatological Subtotal 12(8.0) 4(2.7) Contactdermatitis 5(3.3) 3(2.0) Eczema 5(3.3) 1(0.7)

Citation complémentaire (significativite)

no significant difference between groups (v2-test: P = 0.258). The incidence of dermatological adverse

Tsuboi R, Arano O, Nishikawa T et al.. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.. J Dermatol 2009, DOI 10.1111/j.1346-8138.2009.00673.x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Peut être dû au hasard

Fiedler-Weiss 1986

Essai randomisé, risque de biais élevé. Topical minoxidil dose-response effect in alopecia areata.

CritèreMinoxidil topique 5 %Minoxidil topique 1 %Écart
Taux de repousse clinique patients traites successivement par minoxidil 1 % puis 5 %60 semaines88 %
Voir la citation
Of the 26 patients who treated initially with were Downloaded From: http://archderm.jamanetwork.com/ by a New York University User on 06/07/2015 1% minoxidil and subsequently with 5% minoxidil, 13 (50%) responded to 1% minoxidil compared with 23 (88%) who responded to 5% minoxidil (Table). Of 19 patients with 75% greater hair loss who or were treated in both studies, eight (42%) responded to 1% minoxidil compared with 16 (84%) who responded to 5% minoxidil (Table). The difference in percentage of responders between the two studies highly was significant (Table). The quality of hair regrowth

Citation complémentaire (significativite)

'Response was defined as regrowth of terminal hair at treatment site. tx2. P- .0120. ^Defined as 75% or greater scalp hair loss. §Thesepatientsweretreatedfor48weekswith 1%minoxidil, givennotreatmentforeightmonths,thentreatedwith5%minoxidilfor60weeks,or for 48 weeks iffirst preceded by 12 weeks ofvehicle placebo administration. ¡Exact binomial, P= .0020. HExactbinomial, P= .0078.

Fiedler-Weiss VC, West DP, Buys CM et al.. Topical minoxidil dose-response effect in alopecia areata.. Arch Dermatol 1986. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

50 %
Voir la citation
Of the 26 patients who treated initially with were Downloaded From: http://archderm.jamanetwork.com/ by a New York University User on 06/07/2015 1% minoxidil and subsequently with 5% minoxidil, 13 (50%) responded to 1% minoxidil compared with 23 (88%) who responded to 5% minoxidil (Table). Of 19 patients with 75% greater hair loss who or were treated in both studies, eight (42%) responded to 1% minoxidil compared with 16 (84%) who responded to 5% minoxidil (Table). The difference in percentage of responders between the two studies highly was significant (Table). The quality of hair regrowth

Citation complémentaire (significativite)

'Response was defined as regrowth of terminal hair at treatment site. tx2. P- .0120. ^Defined as 75% or greater scalp hair loss. §Thesepatientsweretreatedfor48weekswith 1%minoxidil, givennotreatmentforeightmonths,thentreatedwith5%minoxidilfor60weeks,or for 48 weeks iffirst preceded by 12 weeks ofvehicle placebo administration. ¡Exact binomial, P= .0020. HExactbinomial, P= .0078.

Fiedler-Weiss VC, West DP, Buys CM et al.. Topical minoxidil dose-response effect in alopecia areata.. Arch Dermatol 1986. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Probablement réel